THERAPY WITH CERTOLIZUMAB PEGOL AND OTHER TNF-A INHIBITORS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS. RESULTS FROM THE CORRONA REGISTRY
Author(s)
Pappas DA1, Etzel CJ2, Bedenbaugh A3, Tambiah J4, Greenberg JD5
1Columbia, New York, NY, USA, 2UT MD Anderson, Houston, TX, USA, 3UCB Pharma, Smyrna, GA, USA, 4UCB, Smyrna, GA, USA, 5NYU School of Medicine, New York, NY, USA
OBJECTIVES: To describe baseline characteristics of elderly patients with Rheumatoid Arthritis (RA) initiating therapy with Certolizumab Pegol ( CZP) and other TNF-a inhibitors (TNFi). METHODS: Cross-sectional analysis of RA patients older than 65 years of age, initiating CZP or another TNFi following enrollment in the CORRONA registry. Baseline demographic and clinical characteristics of included patients were assessed. Each characteristic was compared between CZP and other TNFi initiators using either Student’s two-sample t-test or the chi-square test. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PMS11
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Musculoskeletal Disorders